JKJanardan Khandekar

Janardan Khandekar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Janardan Khandekar has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Sickle Cell Trait with Risk and Mortality of COVID-19: Results from the United Kingdom Biobank

    by W. Kyle Resurreccion, Joseph Hulsizer, Zhuqing Shi, Jun Wei, Chi-Hsiung Wang, Rong Na, S. Lilly Zheng, Clay Struve, Brian T. Helfand, Janardan Khandekar, et al.

    : Sickle cell trait (SCT) carriers inherit one copy of the Glu6Val mutation in the hemoglobin gene and is particularly common in Black individuals (5–10%). Considering the roles of hemoglobin in immune responses and the higher risk for coronavirus disease (COVID-19) among Black individuals, we tested whether Black SCT carriers were at increased risk for COVID-19 infection and mortality according to the United Kingdom Biobank. Among Black individuals who were tested for COVID-19, we found similar infection rates among SCT carriers (14/72; 19.7%) and noncarriers (167/791; 21.1%), but higher COVID-19 mortality rates among SCT carriers (4/14; 28.6%) than among noncarriers (21/167; 12.6%) (odds ratio [OR], 3.04; 95% confidence interval [CI], 0.69–11.82; P = 0.12). Notably, SCT carriers with preexisting diabetes had significantly higher COVID-19 mortality (4/4; 100%) than those without diabetes (0/10; 0%; (OR, 90.71; 95% CI, 5.66–infinite; P = 0.0005). These findings suggest that Black SCT carriers with preexisting diabetes are at disproportionally higher risk for COVID-19 mortality. Confirmation by larger studies is warranted.


  • Open Access

    Association of Cancer with Risk and Mortality of COVID-19: Results from the UK Biobank

    by Zhuqing Shi, W. Kyle Resurreccion, Chi-Hsiung Wang, Jun Wei, Rong Na, S. Lilly Zheng, Liana K. Billings, Brian T. Helfand, Janardan Khandekar, Jianfeng Xu

    Although cancer has been associated with COVID-19 risk and mortality in hospital-based studies, few population-based studies have been reported. Utilizing data from the UK Biobank (UKB), a population-based prospective cohort, we formally tested the association of over 44 different types of cancer with COVID-19 infection and mortality among 7,661 subjects who were tested by June 17, 2020. Compared to non-cancer subjects, cancer subjects (N=1,521) had significantly lower overall risk for COVID-19 infection [odds ratio (OR) and 95% confidence interval (CI): 0.79 (0.68-0.92), P =2.60E-03]. However, a trend of higher risk for COVID-19 mortality was found among 256 COVID-19 positive cancer patients, especially for hematologic cancers such as non-Hodgkin lymphoma [3.82 (1.17-12.01), P=0.02]. In cancer patients, while few demographic, lifestyle, genetic and comorbidity factors predicted risk for COVID-19 infection, older age, male sex, heart disease and hypertension significantly predicted COVID-19 mortality. The lower risk for COVID-19 infection is likely due to extra caution in COVID-19 prevention and more testing among cancer patients, an encouraging finding that demonstrates the feasibility of intervention. These results, if confirmed in future releases of UKB data and other independent populations, may provide guidance for COVID-19 prevention and treatment among cancer patients.


  • Open Access

    Association of Sickle Cell Trait with Risk and Mortality of COVID-19: Results from the UK Biobank

    by W. Kyle Resurreccion, Zhuqing Shi, Jun Wei, Rong Na, S. Lilly Zheng, Joseph Hulsizer, Clay Struve, Brian T. Helfand, Janardan Khandekar, Michael S. Caplan, et al.

    We tested the hypothesis that patients with sickle cell trait (SCT), a common condition in individuals of African descent, have increased risk and mortality for coronavirus disease (COVID-19) in the UK Biobank. By June 17, 2020, 1,550 of 7,668 (20%) tested subjects were positive for COVID-19, including 298 (19%) deaths. Blacks had higher rates than Whites for COVID-19 infections (79/222=36% vs. 1,342/7,010=19%,P=1.28×10−9). Among Blacks, SCT carriers did not have higher infection rates (5/15=33%) than non-SCT carriers (74/207=36%),P=1.00. However, SCT carriers had a trend of higher death rates (2/5=40%) than non-SCT carriers (12/74=16%), although not statistically significant (P=0.21).

  • Open Access

    Direct observation of genomic heterogeneity through local haplotyping analysis

    by Kamalakar Gulukota, Donald L Helseth Jr, Janardan D Khandekar

    It has been an abiding belief among geneticists that multicellular organisms’ genomes can be analyzed under the assumption that a single individual has a uniform genome in all its cells. Despite some evidence to the contrary, this belief has been used as an axiomatic assumption in most genome analysis software packages. In this paper we present observations in human whole genome data, human whole exome data and in mouse whole genome data to challenge this assumption. We show that heterogeneity is in fact ubiquitous and readily observable in ordinary Next Generation Sequencing (NGS) data. Starting with the assumption that a single NGS read (or read pair) must come from one haplotype, we built a procedure for directly observing haplotypes at a local level by examining 2 or 3 adjacent single nucleotide polymorphisms (SNPs) which are close enough on the genome to be spanned by individual reads. We applied this procedure to NGS data from three different sources: whole genome of a Central European trio from the 1000 genomes project, whole genome data from laboratory-bred strains of mouse, and whole exome data from a set of patients of head and neck tumors. Thousands of loci were found in each genome where reads spanning 2 or 3 SNPs displayed more than two haplotypes, indicating that the locus is heterogeneous. We show that such loci are ubiquitous in the genome and cannot be explained by segmental duplications. We explain them on the basis of cellular heterogeneity at the genomic level. Such heterogeneous loci were found in all normal and tumor genomes examined. Our results highlight the need for new methods to analyze genomic variation because existing ones do not systematically consider local haplotypes. Identification of cancer somatic mutations is complicated because of tumor heterogeneity. It is further complicated if, as we show, normal tissues are also heterogeneous. Methods for biomarker discovery must consider contextual haplotype information rather than just whether a variant “is present”.